US FDA Approval of Generic HIV Prevention Shot Marks Shift in Global Access

The United States Food and Drug Administration (FDA) has officially approved a generic version of the twice-yearly HIV prevention injection, lenacapavir. This regulatory milestone, announced by the Indian pharmaceutical manufacturer Dr. Reddy’s Laboratories and the global health initiative Unitaid, represents a significant step toward making advanced HIV prevention tools available at a fraction of their original market cost.

The Path to Affordable Prevention

Lenacapavir, originally developed by the US pharmaceutical firm Gilead, gained initial FDA approval in June 2025. Clinical trials demonstrated that the drug is more than 99.9 percent effective at preventing HIV infection. Unlike daily oral pre-exposure prophylaxis (PrEP) pills, which have been available since 2012 but require strict daily adherence to maintain efficacy, lenacapavir is administered as an injection only twice per year.

While the drug’s clinical success was clear, its high cost in the United States—approximately $28,000 per year—posed a significant barrier to widespread adoption. To address this, Gilead granted voluntary licenses to six generic manufacturers in late 2024, including Dr. Reddy’s Laboratories.

Pricing and Global Distribution

Under a pricing agreement established in September 2025 involving Dr. Reddy’s, Unitaid, the African health research institute Wits RHI, and the Clinton Health Access Initiative (CHAI), the generic version is slated to be available for $40 per person per year across 120 countries. This dramatic reduction in cost is intended to facilitate access in regions where HIV remains a critical public health challenge.

Deepak Sapra, CEO of Pharmaceutical Services and API at Dr. Reddy’s, noted that the development of this complex injectable required significant manufacturing expertise. Philippe Duneton, executive director of Unitaid, emphasized that the organization’s early involvement was aimed at shortening the gap between scientific innovation and real-world availability.

Regulatory Context

The FDA’s approval of the generic version was granted under the President’s Emergency Plan for AIDS Relief (PEPFAR) program. This framework is designed to expedite the availability of life-saving medications in countries heavily impacted by the HIV epidemic. According to data provided by Unitaid, more than 125,000 individuals across 10 early-adopter African nations have already begun using the original version of lenacapavir, indicating a strong existing demand for long-acting injectable prevention methods.

Conclusion

The introduction of a low-cost generic lenacapavir marks a pivotal moment in the global effort to combat HIV, a disease that has claimed over 40 million lives over the past four decades. By lowering the financial barrier to entry, health organizations hope to transition from daily pill regimens to more reliable, long-acting prevention strategies, potentially altering the trajectory of the epidemic in the most affected regions of the world.

<

p class=”vbna-source-note”>Source: Channels Television

Tags: FDA · Global Health · HIV · news · Pharmaceuticals · Public Health · ViralBrief